Denali Capital shareholders approve extension to Dec 2025; ~708K shares redeemed for ~$8.6M

Semnur Pharmaceuticals, Inc.

Shareholders voted to extend business combination deadline to December 11, 2025, via up to 8 monthly extensions.
Holders of ~708,098 Class A shares redeemed for ~$8.6M (~$12.17/share); only 43,739 Class A shares remain outstanding.
Company deposited $874.78 into trust for first extension to May 11, 2025, funded by Scilex convertible note (up to $180K).
Scilex note bears no interest, convertible at $10/share; remaining $58,670.30 available for future extensions.

item 5.07 item 8.01 item 9.01

Machine-readable event card

schema_version: secwatch.filing_event.v1
accession: 0001213900-25-032299
form_type: 8-K
ticker: SMNR
cik: 0001913577
company_name: Semnur Pharmaceuticals, Inc.
filed_at: 2025-04-16T23:59:59+00:00
discovered_at: 2026-05-14T18:02:50.457125+00:00
generated_at: 2026-05-23T13:56:40.371672+00:00
sec_items: ["5.07", "8.01", "9.01"]
event_type: other_material
sentiment: neutral
materiality_score: 0.6
confidence: high
secwatch_canonical_url: https://secwatch.observer/filing/0001213900-25-032299
json_url: https://secwatch.observer/filing/0001213900-25-032299.json
markdown_url: https://secwatch.observer/filing/0001213900-25-032299.md
text_url: https://secwatch.observer/filing/0001213900-25-032299.txt
edgar_index_url: https://www.sec.gov/Archives/edgar/data/1913577/000121390025032299/0001213900-25-032299-index.htm
edgar_primary_document_url: https://www.sec.gov/Archives/edgar/data/1913577/000121390025032299/ea0238488-8k_denali.htm
generated_by_model: deepseek-v4-flash:cloud@v2
review_status: machine_generated
human_reviewed: false
corrected: false
correction_note: null
correction_timestamp: null
superseded_by: null

JSON Markdown Plain text

Source: SEC EDGAR

accession 0001213900-25-032299

view filing index on sec.gov

view primary document

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.